Clinical trial
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants
NCT01900652
Study timeline
Study start (unknown)2013-08-01Date precision: month
Registry last updated2019-09-18
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Carcinoma, Non-Small-Cell Lungunresolved
Interventions
EmibetuzumabDRUG
ErlotinibDRUG · verified · RxNorm: erlotinib
Sponsors & collaborators
Eli Lilly and Companylead sponsor
Mapped research locations
SeattleWashington, United States2New YorkNew York, United States1BostonMassachusetts, United States1Los AngelesCalifornia, United States1PhiladelphiaPennsylvania, United States1St LouisMissouri, United States1AtlantaGeorgia, United States1NashvilleTennessee, United States1SeoulSouth Korea1BirminghamAlabama, United States1CincinnatiOhio, United States1TampaFlorida, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01900652 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.